
==== Front
Support Care Cancer
Support Care Cancer
Supportive Care in Cancer
0941-4355
1433-7339
Springer Berlin Heidelberg Berlin/Heidelberg

39196463
8785
10.1007/s00520-024-08785-9
Research
Oncology researchers’ and clinicians’ perceptions of complementary, alternative, and integrative medicine: an international, cross-sectional survey
http://orcid.org/0000-0003-0031-5873
Ng Jeremy Y. jeremy.ng@med.uni-tuebingen.de
ngjy2@mcmaster.ca

12
http://orcid.org/0009-0003-1036-7930
Kochhar Jassimar 12
http://orcid.org/0000-0002-3640-8046
Cramer Holger 12
1 grid.411544.1 0000 0001 0196 8249 Institute of General Practice and Interprofessional Care, University Hospital Tübingen, Tübingen, Germany
2 grid.6584.f 0000 0004 0553 2276 Robert Bosch Center for Integrative Medicine and Health, Bosch Health Campus, Stuttgart, Germany
28 8 2024
28 8 2024
2024
32 9 6153 3 2024
2 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Complementary, alternative, and integrative medicine (CAIM) has become an increasingly popular supportive therapy option for patients with cancer. The objective of this study was to investigate how researchers and clinicians in the oncology field perceive CAIM.

Methods

We conducted an online, anonymous, cross-sectional survey for researchers and clinicians who have published their work in oncology journals that are indexed in MEDLINE. The link to the survey was sent to 47, 991 researchers and clinicians whose contact information was extracted from their publications. The survey included various multiple-choice questions, and one open-ended question at the end to allow for any additional comments.

Results

751 respondents completed the survey, and they mostly identified themselves as researchers (n = 329, 45.13%), or as both researchers and clinicians (n = 332, 45.45%) in the field of oncology. Over half of the respondents perceive mind–body therapies (n = 354, 54.97%) to be the most promising CAIM category with regards to the prevention, treatment, and/or management of diseases related to oncology, and many respondents agreed that most CAIM therapies are safe (n = 218, 37.39%), and that clinicians should receive training on CAIM therapies via formal (n = 225, 38.59%) and supplemental education (n = 290, 49.83%). However, many respondents were unsure when asked if most CAIM therapies are effective (n = 202, 34.77%).

Conclusions

The findings from this study demonstrated great current interest in the use of CAIM in oncology. This information can serve as a foundation for conducting additional research and creating customized educational materials for researchers and clinicians in oncology.

Keywords

Complementary and alternative medicine
Integrative medicine
Oncology
Perceptions
Cancer
Universitätsklinikum Tübingen (8868)Open Access funding enabled and organized by Projekt DEAL.

issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcBackground

Cancer, although commonly interpreted as a single illness, comprises over 100 different diseases, all of which develop from abnormalities within fundamental aspects of the cell growth cycle [1–5]. The global burden of cancer continues to increase, largely fuelled by aging populations and a greater prevalence of cancer-promoting behaviours [6]. In 2020 alone, the GLOBOCAN estimate appraised the global prevalence of cancer as 19.3 million new cases and almost 10.0 million deaths [7]. Chemotherapy, radiotherapy, and surgery are among the most common types of cancer treatments, and novel approaches to cancer management such as immunotherapy, stem cell therapy, and nanoparticles are continuously advancing [8, 9]. Although essential for curative cancer treatment, these treatment strategies pose a vast array of adverse effects that are both physically and emotionally taxing on patients [9]. Therefore, due to negative adverse effects associated with existing cancer therapies, patients with cancer may be increasingly inclined to explore management strategies, such as complementary, alternative, and integrative medicine (CAIM).

CAIM usage has experienced increasing popularity among patients in recent years, and individuals diagnosed with cancer are no exception [10–14]. The US National Center for Complementary and Integrative Health (NCCIH) has defined “complementary medicine” as a non-mainstream approach used together with conventional medicine, whereas “alternative medicine” is defined as a non-mainstream approach used in place of conventional medicine [15]. Moreover, “integrative medicine” is the coordination of conventional and complementary approaches, thus emphasizing the use of multimodal interventions to develop combinations of health approaches centred around holistic care/treatment [15–17]. For the purpose of this study, we will collectively refer to this group of diverse therapies as CAIM. Examples of CAIM include acupuncture, mind–body practices such as yoga, herbal supplements, music/art therapy, and chiropractic therapy [15–22]. There has been an increase in CAIM usage by patients with cancer in order to moderate side effects of invasive treatments (chemotherapy and radiation) and for perceived benefits such as health promotion, disease symptom management, illness prevention, and immune function improvement [23–25]. For example, a 2011 meta-analysis conducted by Horneber et al. reported that 49% of patients with cancer throughout 18 selected countries currently used CAIM [26], and many studies have found that patients with cancer use it as a supportive measure to alleviate associated symptoms or the side effects of curative therapy [23, 27–33].

However, despite the relatively high prevalence of CAIM use among patients with cancer, healthcare professionals lack knowledge about the safety and efficacy of CAIMs [34], and current literature lacks evidence-based information regarding the safety, efficacy, and benefits of CAIMs in oncological settings [35–37]. As a result, healthcare professionals are often unequipped to discuss the potential harms and benefits of CAIMs with patients and lack guidance pertaining to CAIM recommendations in oncology clinical practice guidelines [38]. This has led to inconsistent guidance from physicians regarding the integration of CAIMs into conventional healthcare settings [30]. This has also led over half of patients with cancer to avoid discussing their use of CAIM with clinicians due to concerns such as clinicians’ lack of knowledge and interest regarding CAIM [39–43].

Therefore, given the growing prevalence of CAIM among patients with cancer and the debates surrounding its validity within healthcare, it is evident that a better understanding of the perceptions of oncology medical researchers and clinicians towards CAIM is required. An exploration of this sort would highlight the reservations and support that oncology clinicians and researchers demonstrate towards CAIM and may address the gaps in current literature pertaining to clinicians’ and researchers’ perspectives on CAIM. Therefore, the objective of this study is to collect data on perceptions of oncology researchers and clinicians regarding CAIM.

Methods

Transparency statement

Approval was granted by the Research Ethics Board at the University Hospital Tübingen before beginning this project (REB Number: 389/2023BO2). Prior to recruiting participants, the study protocol was registered and made available on the Open Science Framework (OSF) [44].

Study design

The study was carried out as an online, anonymous, cross-sectional survey targeting researchers and clinicians who have published in oncology medical journals indexed in MEDLINE [45].

Sampling framework

A complete sample of corresponding authors who have published articles in oncology journals indexed in MEDLINE within approximately the past 3 years (between August 1st, 2020, and May 1st, 2023) were chosen. The selection involved all cancer journals [46] indexed on https://journal-reports.nlm.nih.gov/broad-subjects/. The NLM IDs of the selected journals were first extracted, after which a search strategy based on such IDs was completed on OVID MEDLINE. The resulting list of PubMed IDs (PMIDs) identified through the search was exported as a.csv file in batches of 2000 records at a time and inputted into an R script in batches of 200 PMIDs at a time. The R script subsequently retrieved authors’ names, affiliation institutions, and email addresses (developed based on the easyPubMed package: https://cran.r-project.org/web/packages/easyPubMed/index.html). The study included authors who had published manuscripts of any type.

Participant recruitment

The sampling framework was used to generate a contact list comprising of individuals primarily assumed to be oncology researchers and clinicians based on their publication of articles in oncology journals indexed in MEDLINE. It was expected that the curated list contained duplicate email addresses due to participants potentially contributing/authoring multiple manuscripts within our sample, thus, duplicate addresses were removed from the dataset prior to recruitment emails being sent out. Furthermore, to account for any incorrect author names retrieved during our search, we attempted to correct such (where possible) through a Google search, rather than completely omitting the incorrectly retrieved name from our sample. The platform that was used to both send the emails and create the survey itself was SurveyMonkey [47]. An email which outlined the study’s objectives and provided a survey link was sent to potential participants. Upon clicking the survey link, potential participants were directed to the initial page of the survey. They were then prompted to confirm their consent to the specified terms and conditions associated with survey participation. Only those who responded with a “Yes” were granted access to view and respond to the survey questions. Participants were sent reminder emails during the first, second, and third weeks following the initial invitation email, after which participants were provided with a total of four weeks after the third (final) reminder to complete the survey. The survey was open from August 29, 2023 to November 13, 2023. Participants were able to skip any questions within the survey that they did not wish to answer.

Survey design

The survey was provided to all participants in English. The first page of the survey asked participants a screening question, which was followed by a series of demographic questions. Throughout the rest of the survey, participants were asked to provide their perceptions on CAIM and a multiple-choice format was used for the majority of the survey questions. Certain questions were only asked to clinicians, this included “Please select all that apply with regards to CAIM therapies that your patients have sought counselling or disclosed using”, “Among patients you have seen during the past year, approximately what percentage disclose using CAIM or seek your counselling on CAIM therapies”, “In which of the following areas have you practiced or recommended CAIM to your patients,” “In which of the following areas have you received formal training”, “In which of the following areas have you received supplemental training”, and “Please select if you would be comfortable counselling and/or recommending most CAIM therapies to my patients.” Two independent CAIM researchers pilot tested the survey by providing their feedback to the questions detailed within such prior to its distribution. A copy of the survey can be found at the following link: https://osf.io/kb2zp.

Data management and analysis

Quantitative data obtained from the multiple-choice questions were analyzed and used to generate basic descriptive statistics, such as counts and percentages. Furthermore, the qualitative data from the one open-ended question were analyzed through a thematic content analysis [48]. This entailed the responses being interpreted and being assigned a distinct code, which was a representation of the main component of their response.

Results

Demographics

In total, 47 991 emails were sent, with 25 651 being unopened while 6605 bounced. The survey had 751 responses in total (1.8% response rate of unopened and opened, and 4.7% of just the opened). Raw survey data is available at https://osf.io/a94rp. Additionally, crosstabs for key demographic variables (age, career stage, researcher vs. clinician, sex, and WHO regions) are available for download at: https://osf.io/fv62y/. The survey took approximately 9 min to complete. Approximately the same number of respondents indicated that they self-identify as a researcher (n = 329, 45.13%), and as both a researcher and a clinician (n = 332, 45.45%) in the field of oncology. In terms of World Health Organization World Regions, the majority of respondents were from Europe (n = 315, 45.32%) and the Americas (n = 210, 30.22%). Over half of respondents described themselves as faculty members/principal investigators (n = 356, 51.22%), with the next most common being clinicians such as physicians, nurses, etc. (n = 288, 41.44%). Most respondents also described themselves as a senior researcher or clinician with > 10 years of starting their career post formal education (n = 417, 60%). The primary research area of most respondents was clinical research (n = 416, 68.53%). The full information regarding participant characteristics can be found in Table 1.Table 1 Characteristics of Survey Participants

Sex (n = 695)	
  Male	335 (48.20%)	
  Female	346 (49.78%)	
  Intersex	0 (0.00%)	
  Prefer not to say	14 (2.01%)	
  Prefer to self describe	0 (0.00%)	
Age (n = 696)	
  Under 18	0 (0.00%)	
  18–24	1 (0.14%)	
  25–34	91 (13.04%)	
  35–44	206 (29.60%)	
  45–54	189 (27.16%)	
  55–64	138 (19.83%)	
  65 or older	60 (8.62%)	
  Prefer not to say	11 (1.58%)	
Visible Minority (n = 691)	
  Yes	112 (16.21%)	
  No	545 (78.87%)	
  Prefer not to say	34 (4.92%)	
World Health Organization World Region (n = 695)	
  Africa	10 (1.44%)	
  Americas	210 (30.22%)	
  Eastern Mediterranean	22 (3.17%)	
  Europe	315 (45.32%)	
  South-East Asia	74 (10.65%)	
  Western Pacific	46 (6.62%)	
  Prefer not to say	18 (2.59%)	
  Current Position (n = 695)	
  Clinician Student	1 (0.14%)	
  Clinician	288 (41.44%)	
  Graduate student	27 (3.68%)	
  Postdoctoral fellow	50 (7.19%)	
  Faculty member/principal investigator	356 (51.22%)	
  Research support staff	20 (2.88%)	
  Scientist in academia	164 (23.60%)	
  Scientist in industry	9 (1.29%)	
  Scientist in third sector	12 (1.73%)	
  Government scientist	14 (2.01%)	
  Other	18 (2.59%)	
Career Stage (n = 695)	
  Graduate or clinician student	11 (1.58%)	
  Early career researcher or clinician (< 5 years post education)	118 (16.98%)	
  Mid-career researcher or clinician (5–10 years post education)	149 (21.44%)	
  Senior researcher or clinician (> 10 years post education)	417 (60.00%)	
Primary research area (n = 607)	
  Clinical research	416 (68.53%)	
  Preclinical research – in vivo	121 (19.93%)	
  Preclinical research – in vitro	116 (19.11%)	
  Health systems research	57 (9.39%)	
  Health services research	120 (19.77%)	
  Methods research	70 (11.53%)	
  Epidemiological research	117 (19.28%)	
  Other	41 (6.75%)	

Complementary, alternative, and integrative medicine

Most respondents had never conducted research in any area of CAIM (n = 415, 68.82%). Over half of the respondents perceived mind–body therapies (n = 354, 54.97%) to be the most promising CAIM category with regards to the prevention, treatment, and/or management of diseases related to oncology, with biologically based practices being the next most promising (n = 278, 43.17%) (Fig. 1). Many respondents also declared that their patients have sought counselling or disclosed using biologically based practices (n = 270, 79.18%) and whole medical systems (n = 224, 65.69%). It was also indicated by respondents that most commonly, only 0–10% (n = 112, 33.04%) of their patients disclosed that they used CAIM or asked for their counselling on CAIM. When asked in which area of CAIM the respondents have practiced or recommended to their patients, most said mind–body therapies (n = 139, 40.76%), and that they have not practiced or recommended CAIM to their patients (n = 127, 37.24%). A high number of participants also said that they had not received any formal (n = 269, 79.35%) or supplemental (n = 223, 65.98%) training in any of the areas of CAIM. The majority of respondents indicated that the resource they used to learn more about CAIM was academic literature (n = 580, 89.78%). When asked about CAIM in general and to what degree they agreed with a series of statements, some respondents selected the option “agree” that most CAIM therapies are safe (n = 218, 37.39%), that there is value to conducting research on CAIM therapies (n = 307, 52.66%), that more research funding should be allocated to study CAIM therapies (n = 224, 38.42%), and that clinicians should receive training on CAIM therapies via formal (n = 225, 38.59%) and supplemental education (n = 290, 49.83%) (Fig. 2). However, respondents selected “neither agree nor disagree” when asked if most CAIM therapies are effective (n = 202, 34.77%), if most CAIM therapies should be integrated into mainstream medical practice (n = 164, 28.13%), and if insurance companies should cover the cost of most CAIM therapies (n = 198, 34.08%). Respondents selected “disagree” when asked if they would be comfortable counselling their patients about most CAIM therapies (n = 96, 31.27%), and if they would be comfortable recommending most CAIM therapies to their patients (n = 101, 33.01%).Fig. 1 CAIM Category Perceived to be the Most Promising (N = 644)

Fig. 2 Agreement with the Following Statements Regarding CAIM in General (N = 583)

Mind body therapies

When asked about mind–body therapies such as meditation, biofeedback, hypnosis, and yoga, most respondents selected “agree” that this therapy is safe (n = 329, 56.63%), that there is value to conducting research on this therapy (n = 323, 55.79%), that more research funding should be allocated to study this therapy (n = 242, 41.72%), that clinicians should receive training on this therapy via formal (n = 231, 39.83%) and supplemental education (n = 299, 51.64%). Conversely, respondents were unsure, and selected “neither agreed nor disagree” that mind–body therapies are effective (n = 266, 45.86%), that most mind–body therapies should be integrated into mainstream medical practice (n = 208, 35.80%), and that insurance companies should cover the cost of mind–body therapies (n = 216, 37.31%) (Fig. 3). Some respondents also selected “agree” when asked if they would be comfortable counselling their patients about most mind–body therapies (n = 95, 31.15%), and if they would be comfortable recommending most mind–body therapies to their patients (n = 90, 29.70%).Fig. 3 Agreement with the Following Statements Regarding Mind–Body Therapies (N = 581)

Biologically based practices

Next, participants were asked about biologically based practices such as vitamins and dietary supplements, botanicals, and special foods. Respondents selected “agree” that there is value to conducting research on this therapy (n = 313, 54.34%), that more research funding should be allocated to study this therapy (n = 223, 38.99%), and that clinicians should receive training on this therapy via formal (n = 211, 36.70%) and supplemental education (n = 239, 41.71%). Respondents were undecided, and selected “neither agree nor disagree” that most biologically based practices are safe (n = 217, 37.67%), effective (n = 226, 39.44%), should be integrated into mainstream medical practice (n = 193, 33.51%%), and that insurance companies should cover the cost of most biologically based practices (n = 224, 38.96%) (Fig. 4). They also selected “disagree” when asked if they would be comfortable counselling (n = 80, 26.32%) and recommending (n = 96, 29.18%) most biologically based practices to patients.Fig. 4 Agreement with the Following Statements Regarding Biologically Based Practices (N = 576)

Manipulative and body-based practices

The next CAIM therapy that participants were asked about was manipulative and body-based practices, which encompasses massage, chiropractic therapy, and reflexology. Participants selected “agree” when asked if there is value to conducting research on this therapy (n = 272, 47.47%) and if clinicians should receive training on this therapy via supplementary education (n = 224, 39.23%). However, they were uncertain, and chose “neither agree nor disagree” when asked if most manipulative and body-based practices are safe (n = 218, 37.98%), effective (n = 238, 41. 54%), that they should be integrated into mainstream medicine (n = 226, 33.37%), that more research funding should be allocated to study this therapy (n = 196, 34.27%), that insurance companies should cover the cost of this therapy (n = 215, 37.52%), and that clinicians should receive training via formal education (n = 191, 33.39%) (Fig. 5). Respondents were also unsure and selected “neither agree nor disagree” regarding if they would be comfortable counselling patients about most manipulative and body-based practices (n = 95, 31. 35%), and selected “disagree” that they would be comfortable recommending most manipulative and body-based practices to their patients (n = 94, 30.92%).Fig. 5 Agreement with the Following Statements Regarding Manipulative and Body-Based Practices (N = 574)

Biofield therapies

Biofield therapies include practices such as Reiki and therapeutic touch. Respondents only selected “agree” to one statement for this therapy, which is that there is value to conducting research on this topic (n = 200, 35.03%). However, they were divided and selected “neither agree nor disagree” when asked if they believe most biofield therapies are safe (n = 262, 45.96%), effective (n = 259, 45.52%), that they should be integrated into mainstream medical practice (n = 225, 39.40%), that more research funding should be allocated to study this therapy (n = 192, 33.68%), that insurance companies should cover the cost of these therapies (n = 226, 39.65%), and that clinicians should receive training on this therapy via formal (n = 199, 34.97%), or supplemental (n = 212, 37.32%) education (Fig. 6). Respondents also selected “disagree” that they would be comfortable counselling patients about most biofield therapies (n = 98, 32.45%), and “strongly disagree” (n = 96, 32.00%) and “disagree” (n = 96, 32.00%) in equal percentages when asked if they would be comfortable recommending biofield therapies to patients.Fig. 6 Agreement with the Following Statements Regarding Biofield Therapies (N = 571)

Whole medical systems

Respondents were finally asked about whole medical systems, which includes Ayurvedic medicine, traditional Chinese medicine, acupuncture, homeopathy, and naturopathic medicine. The respondents selected “agree” that there is value to conducting research on this therapy (n = 268, 46. 94%), that more research funding should be allocated to study this therapy (n = 195, 34.21%), and that clinicians should receive training on this therapy via supplemental education (n = 210, 37.04%). They were unsure and selected “neither agree nor disagree”, however, when asked if most manipulative and body-based practices are safe (n = 234, 40.91%), are effective (n = 226, 39.51%), whether they should be integrated into mainstream medicine (n = 199, 34.79%), whether insurance companies should cover the cost of this therapy (n = 218, 38.18%), and whether clinicians should receive training via formal education (n = 185, 32.34%) (Fig. 7). They also selected “disagree” when asked if they would be comfortable counselling patients about whole medical systems (n = 94, 30.92%), and if they would be comfortable recommending whole medical systems to their patients (n = 101, 33.22%).Fig. 7 Agreement with the Following Statements Regarding Whole Medical Systems (N = 572)

Benefits and challenges

The greatest benefits that respondents perceived to be associated with CAIM are ‘holistic approach to health and wellness’ (n = 343, 60.07%), ‘empowerment of patients to take control of their own health’ (n = 325, 56.02%), and ‘increased patient satisfaction and well-being’ (n = 324, 56.74%) (Fig. 8). On the other hand, the most challenging aspects respondents perceived to be associated with CAIM are ‘lack of scientific evidence for safety and efficacy’ (n = 533, 92.70%), ‘lack of standardization in product quality and dosing’ (n = 479, 83.30%), and ‘difficulty in distinguishing legitimate practices from scams or fraudulent claims’ (n = 423, 73. 57%) (Fig. 9).Fig. 8 Benefits Perceived to be Associated with CAIM (N = 571)

Fig. 9 Challenges Perceived to be Associated with CAIM (N = 575)

Thematic analysis

The results yielded 23 codes from the 115 open-ended responses that were received. From these codes, 5 distinct themes were created, which encompass the specific patterns that were established from the dataset. Firstly, “concerns regarding dangers associated with CAIM including false impressions and potential interactions” involved the potential negative consequences that respondents felt were associated with CAIM. Next, “disagrees and is not in support of CAIM” included responses that felt CAIM should not be used in oncology. Also, “more research is required” summarized responses who felt this area needed more evidence-based research to reach a consensus. “In support of specific CAIM for explicit purposes (e.g. emotional/supportive, not curative)” included responses who believed in the usefulness of CAIM for certain distinct purposes. Finally, “belief in integrative approaches in CAIM is beneficial” was indicative of those who believed a holistic approach involving both traditional and CAIM was ideal. Representative quotes from each theme are provided in Table 2; coding and thematic analysis data are available at: https://osf.io/4qny9.Table 2 Thematic Analysis and Representative Quotes

Theme	Representative Quotes	
Concerns regarding dangers with CAIM including false impressions and potential interactions	"I have had many patients reject established therapies in favour of these alternative and apparently integrative approaches—this has been to the detriment of their health overall. I strongly believe many CAIM practitioners are profit-motivated or naive given the negative impact their counselling has on patients health."	"Great misconception about benefit. Many patients use them under the false impression they might help control their cancer and many health professionals go along with that. I have always been honest with my patients that CAIM might make them feel better but will not have any impact on their cancer."	
Disagrees and is not in support of CAIM	"Medicine/oncology is at its best when it is based on facts and not irrational practices of unproven efficacy. CAIM may have a role in palliation, but should not compete with legitimate search for cures."	"…CAIM does not seem to improve oncologic outcomes, is very costly, is incredibly poorly regulated and defined, fraught with fraudulent and ineffective therapies, and often relies on untested traditional remedies that do not meet the standard of evidence required in modern medical practice. I have personally seen multiple vertebral artery dissections from chiropracty, complications from competitive microsomal enzyme inhibition by herbal agents, and patients who refused chemotherapy after reading about "promising" homeopathic strategies. The risks of CAIM far outweigh the benefits and is a particularly egregious scourge on the oncology patient community with low health literacy."	
More research is required	"CAIM cannot have any "special box"-priviledges but it has to go through the same scientific rigorous analysis for efficacy before it will be implemented in any form to general healthcare systems."	"Enormous amounts of resources are wasted on CAIM without proof of safety or efficacy, especially efficacy. Definitive research to determine safety and efficacy is needed, before incorporation into the standard of care, insurance coverage or endorsement by medical professionals."	
In support of specific CAIM for explicit purposes (i.e. emotional/supportive, not curative)	"I believe certain practices such as medidation, diet interventions, etc. are safety and effective. Conversely, others such as vitamin supplementation, etc. are likely not effective and is frequently associated with scams. I think this distinction is important within CAIM practices"	"I'm open minded—having benefited from acupuncture for allergies when conventional treatments didn't work, having used yoga/pilates for breathing disorder when covid disrupted all the services I was meant to have from respiratory physios/SALT practitioners—at their recommendation, and personal experience of how being more active/following better eating habits did help my cancer recovery…"	
Belief in integrative approaches in CAIM is beneficial	"integration with conventional medicine is definitely needed for optimal outcomes!"	"Prudent use of CAIM taking into account drug-drug interactions with mainstream allopathic (chemotherapy etc.) medication should be taken. The use should be incorporated as a holistic approach in treating oncology conditions. The knowledge should be imparted to allopathic practitioners/oncologist based on scientific evidence. We cannot expect them to administer the therapies. But treatment by specialized trained respective therapists of each CAIM should be incorporated in the holistic treatment of the patient."	

Discussion

The objective of this study was to collect data on the perceptions of oncology researchers and clinicians regarding CAIM. It was found that there are mixed perceptions regarding the various CAIM modalities, with more positive perceptions towards mind–body therapies and more negative feelings towards others such as biofield therapies. However, most respondents agreed that there is a need for more research in the field of CAIM in oncology.

Comparative literature

The results align with previous research that has explored healthcare processionals’ views on CAIM. A common theme noted in previous studies is that there is a lack of adequate evidence for the use of CAIM in oncological settings [49, 50]. Additionally, previous studies have found that the risk of interactions between CAIM products and oncological treatment is a significant factor that they must consider in mitigating patient risk [51, 52]. In our study, respondents also felt that these were major concerns for the use of CAIM in oncology, which may be the reason why they chose the option indicating that various CAIM modalities may not be safe and/or effective. Specifically, from the thematic analysis conducted, the theme with the most responses was “concerns regarding dangers associated with CAIM including false impressions and potential interactions” therefore demonstrating their concern. A previous study conducted which examined and compared the perceptions of traditional health care providers with Indigenous Australian healthcare providers in the field of oncology on the use of CAIM also found that the Indigenous providers had a greater understanding and openness towards CAIM [51]. Also, a study conducted in the field of paediatric oncology on opinions surrounding CAIM found that giving false hope to patients was a major concern for healthcare practitioners [53]. It is expected that due to the variability of different malignancies and their respective prognoses, clinicians would want to present their patients with the most evidence-based option for improvement. This is in line with the results of our study, as many respondents were unsure about the safety and effectiveness of some types of CAIM.

Through this study, participants were asked about their perceptions of various CAIM therapies. It was noted that mind–body therapies and biologically based therapies received the most positive responses. Mind–body therapies such as yoga and meditation have been found to have positive outcomes on certain aspects of cancer diagnoses such as improving quality of life, reducing fatigue, improving sleep, and decreasing anxiety [54]. However, it is important to clarify that this modality is not associated with improving cancer outcomes; they merely improve associated symptoms. This could explain why respondents in our study were unsure when asked about the effectiveness of these therapies, and if they should be integrated into mainstream medical practices. Next, biologically based practices encompass modalities such as vitamins and supplements. Evidence-based guidelines are available for oncologists regarding which of these therapies are safe to be integrated into cancer care [55], which may be why the respondents in our study are more inclined to agree with this approach.

The respondents in this study consistently felt that there is value to conducting research in the field of CAIM, across all modalities. Previous studies have also found that the lack of knowledge about CAIM can create a barrier to effective clinician-patient communication [56], due to fear of receiving less care from physicians if patients disclose their use of CAIM [53]. An additional study that compared the perceptions of physicians versus nurses on CAIM found that physicians had reservations regarding a lack of knowledge about the potential value of CAIM [57].

Strengths and limitations

One of the most impactful strengths of our study is that it was able to generalize the perceptions of oncological researchers and clinicians on CAIM, given the large and international sample of individuals who were surveyed. Moreover, during our data collection process, the names and email addresses of study participants were accessed based on the National Library of Medicine (NLM) categorization of such, thus ensuring that the email addresses of a wide variety of authors who have published articles in MEDLINE-indexed oncology journals had been collected. Our study also communicated multiple reminders to prospective study participants with the aim of improving the response rate. Our survey was also sent to individuals who have published in oncology journals throughout the past approximately three years, thus limiting the potential for invalid/inactive email addresses.

Challenges and limitations faced by our study include the possibility of various biases. One bias includes nonresponse bias, which is when the characteristics of non-responders differ from responders [58]. Similarly, recall bias, which may arise due to individuals’ prior exposure to CAIM usage in oncology settings, may have also affected our findings [58]. Moreover, the survey within our study was written and administered in English. Therefore, it is more likely that English-speaking participants completed the survey, possibly having excluded or discouraged non-English clinicians and researchers from providing their perspectives on CAIM.

The methodology of our study also presented various limitations, such as due to our sampling strategy, which involved extracting the names and email addresses of authors of articles published in scholarly oncology journals. It is likely that our study sampled proportionally more researchers than clinicians. In addition, the response rate reported within our study was likely an underestimation of the true value of such. This limitation is enforced by the potential for inactive and invalid email addresses, which may have been a result of changing professions/employers, retiring, or passing away, in addition to the potential that the individuals may have been unavailable during the defined study recruitment period due to reasons such as vacations or leaves of absence. Moreover, one of the inherent challenges associated with studying CAIM such as in this study is the use of the word “effective,” as there are multiple aspects that must be considered such as symptom control, curing the disease, etc. Therefore, this study focuses on gathering general attitudes towards CAIM, as opposed to collecting specific information. Finally, another constraint to bear in mind is that CAIM is a broad term. Despite our classification into five categories (mind–body therapies, biologically based therapies, manipulative and body-based practices, biofield therapies, and whole medical systems), the safety and efficacy profiles vary for each therapy within each category [16]. Consequently, participants were required to formulate generalized opinions on these therapies rather than offering specific insights for each distinct type.

Conclusions

The aim of this study was to understand the perspectives of oncology researchers and clinicians regarding various CAIM therapies. Participants were given the opportunity to rank their views on numerous therapies and offer additional insights they deemed relevant. It was found that mind–body therapies were the most promising category for respondents regarding the prevention, treatment, and/or management of diseases related to oncology. Many respondents also believed that clinicians should receive training on CAIM therapies via formal and supplemental education, thereby reinforcing the idea that this study can serve as a basis for future research, as it yielded valuable understanding into the current perceptions of CAIM within the field of oncology. These findings also demonstrate potential for the development of customized educational resources, given respondent agreement on the potential benefits of further education. For instance, specific educational resources tailored towards clinicians to recommend to their patients regarding the use of a mind–body therapy to treat some of the negative symptoms associated with cancer pain. While past literature has identified patient interest in CAIM, this study stands as the first to specifically address this research question and provide insights into the perceptions of oncology researchers and clinicians. It is anticipated that the outcomes and analysis presented in this study can make meaningful contributions to both the fields of oncology and CAIM, establishing a groundwork for subsequent research endeavours.

Abbreviations

CAIM Complementary, alternative, and integrative medicine

NCCIH National Centre for Complementary and Integrative Health

NLM National Library of Medicine

PMIDs PubMed Identifiers

Acknowledgements

We gratefully acknowledge Nadia Dorca for her contributions to the protocol and data collection.

Authors' contributions

JYN: designed and conceptualized the study, collected and analysed data, drafted the manuscript, and gave final approval of the version to be published. JK: assisted with the collection and analysis of data, made critical revisions to the manuscript, and gave final approval of the version to be published. HC: assisted with the design and concept of the study and the analysis of data, made critical revisions to the manuscript, and gave final approval of the version to be published.

Funding

Open Access funding enabled and organized by Projekt DEAL. This study was unfunded. The authors acknowledge support from the Open Access Publication Fund of the University of Tübingen for the publication of this article.

Data availability

All data and materials associated with this study have been posted on the Open Science Framework and can be found here: https://doi.org/10.17605/OSF.IO/FV62Y.

Declarations

Ethics approval and consent to participate

This study received approval from the University Tübingen Research Ethics board before commencement (REB Number: 389/2023BO2). This research has been conducted in accordance with the Declaration of Helsinki.

Consent for publication

All included study participants consented to participating in this study and to have their survey responses published in a peer reviewed journal.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Faubert B Solmonson A DeBerardinis RJ Metabolic reprogramming and cancer progression Science 2020 368 6487 eaaw5473 10.1126/science.aaw5473 32273439
Faubert B, Solmonson A, DeBerardinis RJ (2020) Metabolic reprogramming and cancer progression. Science 368(6487):eaaw5473. 10.1126/science.aaw547332273439
2. Hausman DM What Is Cancer? Perspect Biol Med 2019 62 4 778 784 10.1353/pbm.2019.0046 31761807
Hausman DM (2019) What Is Cancer? Perspect Biol Med 62(4):778–784. 10.1353/pbm.2019.004631761807
3. Feitelson MA Arzumanyan A Kulathinal RJ Blain SW Holcombe RF Mahajna J Sustained proliferation in cancer: Mechanisms and novel therapeutic targets Semin Cancer Biol 2015 35 S25 54 10.1016/j.semcancer.2015.02.006 25892662
Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J et al (2015) Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol 35:S25-54. 10.1016/j.semcancer.2015.02.00625892662
4. Seyfried TN Huysentruyt LC On the Origin of Cancer Metastasis Crit Rev Oncog 2013 18 1–2 43 73 10.1615/critrevoncog.v18.i1-2.40 23237552
Seyfried TN, Huysentruyt LC (2013) On the Origin of Cancer Metastasis. Crit Rev Oncog 18(1–2):43–73. 10.1615/critrevoncog.v18.i1-2.4023237552
5. Guan X Cancer metastases: challenges and opportunities Acta Pharmaceutica Sinica B 2015 5 5 402 418 10.1016/j.apsb.2015.07.005 26579471
Guan X (2015) Cancer metastases: challenges and opportunities. Acta Pharmaceutica Sinica B 5(5):402–418. 10.1016/j.apsb.2015.07.00526579471
6. Jemal A Bray F Center MM Ferlay J Ward E Forman D Global cancer statistics CA: A Cancer Journal for Clinicians 2011 61 2 69 90 10.3322/caac.20107 21296855
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA: A Cancer Journal for Clinicians 61(2):69–90. 10.3322/caac.2010721296855
7. Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA: A Cancer J Clin 2021 71 3 209 49 10.3322/caac.21660
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer J Clin 71(3):209–49. 10.3322/caac.21660
8. Arruebo M Vilaboa N Sáez-Gutierrez B Lambea J Tres A Valladares M Assessment of the Evolution of Cancer Treatment Therapies Cancers 2011 3 3 3279 330 10.3390/cancers3033279 24212956
Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M et al (2011) Assessment of the Evolution of Cancer Treatment Therapies. Cancers 3(3):3279–33024212956
9. Debela DT Muzazu SG Heraro KD Ndalama MT Mesele BW Haile DC New approaches and procedures for cancer treatment: Current perspectives SAGE Open Med 2021 9 205031212110343 10.1177/20503121211034366
Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC et al (2021) New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med 9:205031212110343
10. WHO (2019) Traditional, Complementary and Integrative Medicine. World Health Organization: WHO; Available from: https://www.who.int/health-topics/traditional-complementary-and-integrative-medicine#tab=tab_3. Accessed 25 Jan 2024
11. Keene MR Heslop IM Sabesan SS Glass BD Complementary and alternative medicine use in cancer: A systematic review Complement Ther Clin Pract 2019 35 33 47 10.1016/j.ctcp.2019.01.004 31003679
Keene MR, Heslop IM, Sabesan SS, Glass BD (2019) Complementary and alternative medicine use in cancer: A systematic review. Complement Ther Clin Pract 35:33–47. 10.1016/j.ctcp.2019.01.00431003679
12. Kemppainen LM Kemppainen TT Reippainen JA Salmenniemi ST Vuolanto PH Use of complementary and alternative medicine in Europe: Health-related and sociodemographic determinants Scandinavian J Public Health 2017 46 4 448 455 10.1177/1403494817733869
Kemppainen LM, Kemppainen TT, Reippainen JA, Salmenniemi ST, Vuolanto PH (2017) Use of complementary and alternative medicine in Europe: Health-related and sociodemographic determinants. Scandinavian J Public Health 46(4):448–455. 10.1177/1403494817733869
13. Eardley S Bishop FL Prescott P Cardini F Brinkhaus B Santos-Rey K A Systematic Literature Review of Complementary and Alternative Medicine Prevalence in EU Complementary Med Res 2012 19 2 18 28 10.1159/000342708
Eardley S, Bishop FL, Prescott P, Cardini F, Brinkhaus B, Santos-Rey K et al (2012) A Systematic Literature Review of Complementary and Alternative Medicine Prevalence in EU. Complementary Med Res 19(2):18–28. 10.1159/000342708
14. De Melo MN Pai P Lam MOY Maduranayagam SG Ahluwalia K Rashad MA The Provision of Complementary, Alternative, and Integrative Medicine Information and Services: a Review of World Leading Oncology Hospital Websites Curr Oncol Rep 2022 24 10 1363 1372 10.1007/s11912-022-01296-y 35639330
De Melo MN, Pai P, Lam MOY, Maduranayagam SG, Ahluwalia K, Rashad MA et al (2022) The Provision of Complementary, Alternative, and Integrative Medicine Information and Services: a Review of World Leading Oncology Hospital Websites. Curr Oncol Rep 24(10):1363–1372. 10.1007/s11912-022-01296-y35639330
15. National Center for Complementary and Integrative Health (NCCIH). Complementary, Alternative, or Integrative Health: What's In a Name? https://www.nccih.nih.gov/health/complementary-alternative-or-integrative-health-whats-in-a-name. Accessed 25 Jan 2024
16. Ng JY Dhawan T Dogadova E Taghi-Zada Z Vacca A Wieland LS Operational definition of complementary, alternative, and integrative medicine derived from a systematic search BMC Complement Med Ther 2022 22 1 104 10.1186/s12906-022-03556-7 35413882
Ng JY, Dhawan T, Dogadova E, Taghi-Zada Z, Vacca A, Wieland LS et al (2022) Operational definition of complementary, alternative, and integrative medicine derived from a systematic search. BMC Complement Med Ther 22(1):104. 10.1186/s12906-022-03556-735413882
17. Ng JY Boon HS Thompson AK Whitehead CR Making sense of “alternative”, “complementary”, “unconventional” and “integrative” medicine: exploring the terms and meanings through a textual analysis BMC Complement Alternative Med 2016 16 1 18 10.1186/s12906-016-1111-3
Ng JY, Boon HS, Thompson AK, Whitehead CR (2016) Making sense of “alternative”, “complementary”, “unconventional” and “integrative” medicine: exploring the terms and meanings through a textual analysis. BMC Complement Alternative Med 16(1):18. 10.1186/s12906-016-1111-3
18. Ng JY Bhatt HA Raja M Complementary and alternative medicine mention and recommendations in pancreatic cancer clinical practice guidelines: A systematic review and quality assessment Integrative Med Res 2023 12 1 100921 10.1016/j.imr.2023.100921
Ng JY, Bhatt HA, Raja M (2023) Complementary and alternative medicine mention and recommendations in pancreatic cancer clinical practice guidelines: A systematic review and quality assessment. Integrative Med Res 12(1):100921. 10.1016/j.imr.2023.100921
19. Ng JY, Sahak H, Lau SKC (2021) A Systematic Review and Quality Assessment of Breast Cancer Clinical Practice Guidelines Providing Complementary and Alternative Medicine Recommendations. Curr Oncol Rep 23(10). 10.1007/s11912-021-01109-8
20. Ng JY, Dogadova E (2021) The Presence of Complementary and Alternative Medicine Recommendations in Head and Neck Cancer Guidelines: Systematic Review and Quality Assessment. Curr Oncol Rep 23(3). 10.1007/s11912-021-01024-y
21. Ng JY Nault H Nazir Z Complementary and integrative medicine mention and recommendations: A systematic review and quality assessment of lung cancer clinical practice guidelines Integrative Med Res 2021 10 1 100452 10.1016/j.imr.2020.100452
Ng JY, Nault H, Nazir Z (2021) Complementary and integrative medicine mention and recommendations: A systematic review and quality assessment of lung cancer clinical practice guidelines. Integrative Med Res 10(1):100452. 10.1016/j.imr.2020.100452
22. Ng JY Kishimoto V Multiple sclerosis clinical practice guidelines provide few complementary and alternative medicine recommendations: A systematic review Complement Ther Med 2021 56 102595 10.1016/j.ctim.2020.102595 33197670
Ng JY, Kishimoto V (2021) Multiple sclerosis clinical practice guidelines provide few complementary and alternative medicine recommendations: A systematic review. Complement Ther Med 56:102595. 10.1016/j.ctim.2020.10259533197670
23. Buckner CA Lafrenie RM Dénommée JA Caswell JM Want DA Complementary and Alternative Medicine Use in Patients Before and After a Cancer Diagnosis Curr Oncol 2018 25 4 275 281 10.3747/co.25.3884 30111968
Buckner CA, Lafrenie RM, Dénommée JA, Caswell JM, Want DA (2018) Complementary and Alternative Medicine Use in Patients Before and After a Cancer Diagnosis. Curr Oncol 25(4):275–281. 10.3747/co.25.388430111968
24. Zaid H Silbermann M Amash A Gincel D Abdel-Sattar E Sarikahya NB Medicinal Plants and Natural Active Compounds for Cancer Chemoprevention/Chemotherapy Evidence-Based Complement Alternative Med 2017 2017 1 2 10.1155/2017/7952417
Zaid H, Silbermann M, Amash A, Gincel D, Abdel-Sattar E, Sarikahya NB (2017) Medicinal Plants and Natural Active Compounds for Cancer Chemoprevention/Chemotherapy. Evidence-Based Complement Alternative Med 2017:1–2. 10.1155/2017/7952417
25. Kessel KA Lettner S Kessel C Bier H Biedermann T Friess H Use of Complementary and Alternative Medicine (CAM) as Part of the Oncological Treatment: Survey about Patients’ Attitude towards CAM in a University-Based Oncology Center in Germany PLoS ONE 2016 11 11 e0165801 10.1371/journal.pone.0165801 27812163
Kessel KA, Lettner S, Kessel C, Bier H, Biedermann T, Friess H et al (2016) Use of Complementary and Alternative Medicine (CAM) as Part of the Oncological Treatment: Survey about Patients’ Attitude towards CAM in a University-Based Oncology Center in Germany. PLoS ONE 11(11):e0165801. 10.1371/journal.pone.016580127812163
26. Horneber M Bueschel G Dennert G Less D Ritter E Zwahlen M How Many Cancer Patients Use Complementary and Alternative Medicine Integr Cancer Ther 2011 11 3 187 203 10.1177/1534735411423920 22019489
Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M (2011) How Many Cancer Patients Use Complementary and Alternative Medicine. Integr Cancer Ther 11(3):187–203. 10.1177/153473541142392022019489
27 Clarke TC The use of complementary health approaches among U.S. adults with a recent cancer diagnosis J Altern Complement Med 2018 24 139 145 10.1089/acm.2016.0182 28930475
Clarke TC (2018) The use of complementary health approaches among U.S. adults with a recent cancer diagnosis. J Altern Complement Med 24:139–145. 10.1089/acm.2016.018228930475
28. Yalcin S Hurmuz P McQuinn L Naing A Prevalence of Complementary Medicine Use in Patients With Cancer: A Turkish Comprehensive Cancer Center Experience J Global Oncol 2018 4 1 6 10.1200/JGO.2016.008896
Yalcin S, Hurmuz P, McQuinn L, Naing A (2018) Prevalence of Complementary Medicine Use in Patients With Cancer: A Turkish Comprehensive Cancer Center Experience. J Global Oncol 4:1–6. 10.1200/JGO.2016.008896
29. Sanford NN Sher DJ Ahn C Aizer AA Mahal BA Prevalence and Nondisclosure of Complementary and Alternative Medicine Use in Patients With Cancer and Cancer Survivors in the United States JAMA Oncol 2019 5 5 735 10.1001/jamaoncol.2019.0349 30973579
Sanford NN, Sher DJ, Ahn C, Aizer AA, Mahal BA (2019) Prevalence and Nondisclosure of Complementary and Alternative Medicine Use in Patients With Cancer and Cancer Survivors in the United States. JAMA Oncol 5(5):735. 10.1001/jamaoncol.2019.034930973579
30. Bahall M (2017) Prevalence, patterns, and perceived value of complementary and alternative medicine among cancer patients: a cross-sectional, descriptive study. BMC Complement Alternative Med 17(1). 10.1186/s12906-017-1853-6
31. Gerson-Cwillich R Serrano-Olvera A Villalobos-Prieto A Complementary and alternative medicine (CAM) in Mexican patients with cancer Clin Transl Oncol 2006 8 3 200 207 10.1007/s12094-006-0011-2 16648120
Gerson-Cwillich R, Serrano-Olvera A, Villalobos-Prieto A (2006) Complementary and alternative medicine (CAM) in Mexican patients with cancer. Clin Transl Oncol 8(3):200–207. 10.1007/s12094-006-0011-216648120
32. Stöcker A Mehnert-Theuerkauf A Hinz A Ernst J Utilization of complementary and alternative medicine (CAM) by women with breast cancer or gynecological cancer PLoS ONE 2023 18 5 e0285718 10.1371/journal.pone.0285718 37172048
Stöcker A, Mehnert-Theuerkauf A, Hinz A, Ernst J (2023) Utilization of complementary and alternative medicine (CAM) by women with breast cancer or gynecological cancer. PLoS ONE 18(5):e0285718. 10.1371/journal.pone.028571837172048
33. Hammersen F Pursche T Fischer D Katalinic A Waldmann A Use of Complementary and Alternative Medicine among Young Patients with Breast Cancer Breast Care 2019 15 2 163 170 10.1159/000501193 32398985
Hammersen F, Pursche T, Fischer D, Katalinic A, Waldmann A (2019) Use of Complementary and Alternative Medicine among Young Patients with Breast Cancer. Breast Care 15(2):163–170. 10.1159/00050119332398985
34. Karim S Benn R Carlson LE Fouladbakhsh J Greenlee H Harris R Henry NL Jolly S Mayhew S Spratke L Walker EM Integrative oncology education: an emerging competency for oncology providers Curr Oncol 2021 28 1 853 862 10.3390/curroncol28010084 33578660
Karim S, Benn R, Carlson LE, Fouladbakhsh J, Greenlee H, Harris R, Henry NL, Jolly S, Mayhew S, Spratke L, Walker EM (2021) Integrative oncology education: an emerging competency for oncology providers. Curr Oncol 28(1):853–862. 10.3390/curroncol2801008433578660
35. Lyman GH Greenlee H Bohlke K Bao T DeMichele AM Deng GE Fouladbakhsh JM Gil B Hershman DL Mansfield S Mussallem DM Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline J Clin Oncol 2018 36 25 2647 2655 10.1200/JCO.2018.79.2721 29889605
Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE, Fouladbakhsh JM, Gil B, Hershman DL, Mansfield S, Mussallem DM (2018) Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. J Clin Oncol 36(25):2647–2655. 10.1200/JCO.2018.79.272129889605
36. Mao JJ Ismaila N Bao T Barton D Ben-Arye E Garland EL Greenlee H Leblanc T Lee RT Lopez AM Loprinzi C Integrative medicine for pain management in oncology: society for integrative oncology–ASCO guideline J Clin Oncol 2022 40 34 3998 4024 10.1200/JCO.22.01357 36122322
Mao JJ, Ismaila N, Bao T, Barton D, Ben-Arye E, Garland EL, Greenlee H, Leblanc T, Lee RT, Lopez AM, Loprinzi C (2022) Integrative medicine for pain management in oncology: society for integrative oncology–ASCO guideline. J Clin Oncol 40(34):3998–4024. 10.1200/JCO.22.0135736122322
37. Carlson LE Ismaila N Addington EL Asher GN Atreya C Balneaves LG Bradt J Fuller-Shavel N Goodman J Hoffman CJ Huston A Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology–ASCO Guideline J Clin Oncol 2023 41 28 4562 4591 10.1200/JCO.23.00857 37582238
Carlson LE, Ismaila N, Addington EL, Asher GN, Atreya C, Balneaves LG, Bradt J, Fuller-Shavel N, Goodman J, Hoffman CJ, Huston A (2023) Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology–ASCO Guideline. J Clin Oncol 41(28):4562–4591. 10.1200/JCO.23.0085737582238
38. Veziari Y, Leach MJ, Kumar S (2017) Barriers to the conduct and application of research in complementary and alternative medicine: a systematic review. BMC Complementary and Alternative Medicine 17(1). 10.1186/s12906-017-1660-0
39. Eng J Ramsum D Verhoef M Guns E Davison J Gallagher R A Population-Based Survey of Complementary and Alternative Medicine Use in Men Recently Diagnosed with Prostate Cancer Integr Cancer Ther 2003 2 3 212 216 10.1177/1534735403256207 15035882
Eng J, Ramsum D, Verhoef M, Guns E, Davison J, Gallagher R (2003) A Population-Based Survey of Complementary and Alternative Medicine Use in Men Recently Diagnosed with Prostate Cancer. Integr Cancer Ther 2(3):212–216. 10.1177/153473540325620715035882
40. Adler S Fosket J Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer J Fam Pract 1999 48 6 453 458 10386489
Adler S, Fosket J (1999) Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. J Fam Pract 48(6):453–45810386489
41. Cohen L Cohen MH Kirkwood C Russell NC Discussing Complementary Therapies in an Oncology Setting J Soc Integr Oncol 2007 05 01 18 10.2310/7200.2006.028
Cohen L, Cohen MH, Kirkwood C, Russell NC (2007) Discussing Complementary Therapies in an Oncology Setting. J Soc Integr Oncol 05(01):18. 10.2310/7200.2006.028
42. Frenkel M Ben-Arye E Cohen L Communication in Cancer Care: Discussing Complementary and Alternative Medicine Integr Cancer Ther 2010 9 2 177 185 10.1177/1534735410363706 20356950
Frenkel M, Ben-Arye E, Cohen L (2010) Communication in Cancer Care: Discussing Complementary and Alternative Medicine. Integr Cancer Ther 9(2):177–185. 10.1177/153473541036370620356950
43 Polich G Dole C Kaptchuk TJ The need to act a little more ‘scientific’: biomedical researchers investigating complementary and alternative medicine Sociology of Health & Illness 2010 32 1 106 22 10.1111/j.1467-9566.2009.01185.x 19891621
Polich G, Dole C, Kaptchuk TJ (2010) The need to act a little more ‘scientific’: biomedical researchers investigating complementary and alternative medicine. Sociology of Health & Illness 32(1):106–22. 10.1111/j.1467-9566.2009.01185.x19891621
44. Ng JY, Dorca N, Cramer H (2023) An International, Cross-Sectional Survey of Oncology Researchers and Clinicians: Perceptions of Complementary, Alternative, and Integrative Medicine [Internet]. OSF. Available from: 10.17605/OSF.IO/HSQ5Z
45. National Library of Medicine. Neoplasms[st] Search Results. Available from: https://www.ncbi.nlm.nih.gov/nlmcatalog?term=Neoplasms%5Bst%5D. Accessed 25 Jan 2024
46. CRAN. easyPubMed Package. Available from: https://cran.r-project.org/web/packages/easyPubMed/index.html. Accessed 25 Jan 2024
47. Survey Monkey. Available from: https://www.surveymonkey.com/. Accessed 25 Jan 2024
48. Joffe H, Yardley L (2004) Content and Thematic Analysis. 10.4135/9781849209793
49. Al-Omari A Al-Qudimat M Hmaidan AA Zaru L Perception and attitude of Jordanian physicians towards complementary and alternative medicine (CAM) use in oncology Complement Ther Clin Pract 2013 19 2 70 76 10.1016/j.ctcp.2013.01.002 23561063
Al-Omari A, Al-Qudimat M, Hmaidan AA, Zaru L (2013) Perception and attitude of Jordanian physicians towards complementary and alternative medicine (CAM) use in oncology. Complement Ther Clin Pract 19(2):70–76. 10.1016/j.ctcp.2013.01.00223561063
50. O'Beirne M, Verhoef M, Paluck E, Herbert C (2004) Complementary therapy use by cancer patients. Physicians' perceptions, attitudes, and ideas. Canadian Family Physician 50(6):882–8. https://pubmed.ncbi.nlm.nih.gov/15233371/. Accessed 25 Jan 2024
51. Gall A Anderson K Adams J Matthews V Garvey G An exploration of healthcare providers’ experiences and perspectives of Traditional and complementary medicine usage and disclosure by Indigenous cancer patients BMC Complement Altern Med 2019 19 1 9 10.1186/s12906-019-2665-7 30606178
Gall A, Anderson K, Adams J, Matthews V, Garvey G (2019) An exploration of healthcare providers’ experiences and perspectives of Traditional and complementary medicine usage and disclosure by Indigenous cancer patients. BMC Complement Altern Med 19:1–9. 10.1186/s12906-019-2665-730606178
52. Stub T Quandt SA Arcury TA Sandberg JC Kristoffersen AE Musial F Salamonsen A Perception of risk and communication among conventional and complementary health care providers involving cancer patients’ use of complementary therapies: a literature review BMC Complement Altern Med 2016 16 1 4 10.1186/s12906-016-1326-3 26729470
Stub T, Quandt SA, Arcury TA, Sandberg JC, Kristoffersen AE, Musial F, Salamonsen A (2016) Perception of risk and communication among conventional and complementary health care providers involving cancer patients’ use of complementary therapies: a literature review. BMC Complement Altern Med 16:1–4. 10.1186/s12906-016-1326-326729470
53. Handayani K Susilawati D Mulatsih S Kaspers GJ Mostert S Sitaresmi MN Health-care providers’ perception and communication about traditional and complementary medicine in childhood cancer in Indonesia Pediatric Hematol Oncol J 2022 7 1 4 9 10.1016/j.phoj.2022.01.003
Handayani K, Susilawati D, Mulatsih S, Kaspers GJ, Mostert S, Sitaresmi MN (2022) Health-care providers’ perception and communication about traditional and complementary medicine in childhood cancer in Indonesia. Pediatric Hematol Oncol J 7(1):4–9. 10.1016/j.phoj.2022.01.003
54. Stritter W Everding J Luchte J Eggert A Seifert G Yoga, Meditation and Mindfulness in pediatric oncology− A review of literature Complement Ther Med 2021 1 63 102791 10.1016/j.ctim.2021.102791
Stritter W, Everding J, Luchte J, Eggert A, Seifert G (2021) Yoga, Meditation and Mindfulness in pediatric oncology− A review of literature. Complement Ther Med 1(63):102791. 10.1016/j.ctim.2021.102791
55. Frenkel M, Ben-Arye E, Baldwin CD, Sierpina V (2005) Approach to communicating with patients about the use of nutritional supplements in cancer care. South Med J 98(3):289–94. https://pubmed.ncbi.nlm.nih.gov/15813155/
56. Broom A Adams J Oncology clinicians' accounts of discussing complementary and alternative medicine with their patients Health 2009 13 3 317 36 10.1177/1363459308101 19366839
Broom A, Adams J (2009) Oncology clinicians’ accounts of discussing complementary and alternative medicine with their patients. Health 13(3):317–36. 10.1177/136345930810119366839
57. Pamela S Alex B Vanessa B Jon A Attitudes toward complementary and alternative medicine amongst oncology professionals in Brazil Complement Ther Med 2016 1 27 30 34 10.1016/j.ctim.2016.04.003
Pamela S, Alex B, Vanessa B, Jon A (2016) Attitudes toward complementary and alternative medicine amongst oncology professionals in Brazil. Complement Ther Med 1(27):30–34. 10.1016/j.ctim.2016.04.003
58. Wang X Cheng Z Cross-Sectional Studies Chest 2020 158 1 S65 71 10.1016/j.chest.2020.03.012 32658654
Wang X, Cheng Z (2020) Cross-Sectional Studies. Chest 158(1):S65-71. 10.1016/j.chest.2020.03.01232658654
